The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
11 citations
,
April 2020 in “Andrology” Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
September 2011 in “Urology” Urinary PSA could be an early marker for enlarged prostate.
21 citations
,
January 1998 in “Urologia internationalis” All treatments helped with prostate symptoms, but the combination of dibenyline and finasteride worked best without extra side effects.
14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” Finasteride helps with prostate symptoms but may cause sexual side effects.
4 citations
,
February 2016 in “The Journal of urology/The journal of urology” Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
3 citations
,
January 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.
2 citations
,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.